论文部分内容阅读
目的:探讨雌激素诱导蛋白pS2的表达与乳腺癌临床参数和辅助三苯氧胺TAM治疗疗效的关系,明确pS2对辅助内分泌治疗的指导地位。方法:采用免疫组化S蛳P法检测81例ER阳性原发乳腺癌的石蜡切片pS2的表达, 统计学分析其与预后的关系。结果:原发乳腺癌pS2的阳性表达率为66.7 %,其表达与手术年龄(P=0.037)、月经状态(P=0.016)、肿瘤大小(P=0.029)、PR表达情况(P<0.001)密切相关,年龄小于50岁、绝经前、小肿瘤、PR阳性的患者pS2阳性率高。单因素分析和多因素分析均表明pS2是预测OS的独立预后因子。同时pS2对DFS也具有独立预后价值(P=0.023)。结论:pS2是预测ER阳性乳腺癌患者辅助内分泌治疗疗效的独立指标。
OBJECTIVE: To investigate the relationship between the expression of estrogen-inducible protein pS2 and the clinical parameters of breast cancer and the efficacy of adjuvant tamoxifen TAM and to determine the guiding role of pS2 in adjuvant endocrine therapy. Methods: Immunohistochemical S 蛳 P method was used to detect the expression of pS2 in paraffin-embedded sections of 81 cases of ER-positive primary breast cancer, and its relationship with prognosis was statistically analyzed. Results: The positive expression rate of pS2 in primary breast cancer was 66.7%. The expression of pS2 in primary breast cancer was significantly correlated with age of surgery (P = 0.037), menstrual status (P = 0.016), tumor size (P = 0.029) Closely related, age less than 50 years old, premenopausal, small tumors, PR positive patients pS2-positive rate. Univariate and multivariate analysis showed that pS2 was an independent predictor of OS. PS2 also had independent prognostic value for DFS (P = 0.023). Conclusion: pS2 is an independent predictor of adjuvant endocrine therapy in patients with ER-positive breast cancer.